Profile data is unavailable for this security.
About the company
IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.
- Revenue in GBP (TTM)6.67m
- Net income in GBP-1.18m
- Incorporated1995
- Employees89.00
- LocationIXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
- Phone+44 203 763 7499
- Fax+44 207 209 2473
- Websitehttps://ixico.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuformix PLC | 0.00 | -436.95k | 1.56m | 2.00 | -- | 0.3371 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
N4 Pharma PLC | 0.00 | -925.31k | 2.22m | 5.00 | -- | 1.33 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -59.56 | -58.71 | -65.34 | -63.61 | -- | -- | -- | -8,155.51 | -- | -1,910.05 | 0.00 | -- | -- | -- | 33.35 | -- | -- | -- |
Hellenic Dynamics PLC | -100.00bn | -100.00bn | 3.09m | 25.00 | -- | 3.90 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
Evgen Pharma PLC | 838.00k | -3.35m | 3.31m | 7.00 | -- | 0.5414 | -- | 3.95 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
Fusion Antibodies PLC | 1.58m | -2.84m | 3.62m | 50.00 | -- | 1.55 | -- | 2.30 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 3.86m | 7.00 | -- | 1.75 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
IXICO PLC | 6.67m | -1.18m | 4.23m | 89.00 | -- | 0.3701 | -- | 0.6348 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
ValiRx Plc | 0.00 | -2.41m | 4.80m | 8.00 | -- | 0.8823 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
BSF Enterprise PLC | 12.94k | -1.50m | 5.43m | 4.00 | -- | 1.12 | -- | 419.26 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
Genflow Biosciences PLC | 0.00 | -1.18m | 5.51m | 0.00 | -- | 2.68 | -- | -- | -0.004 | -0.004 | 0.00 | 0.0059 | 0.00 | -- | -- | -- | -48.01 | -- | -51.61 | -- | -- | -- | -- | -- | -- | -6,299.75 | 0.00 | -- | -- | -- | -35.13 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BGF Investment Management Ltd.as of 04 Dec 2023 | 8.92m | 18.46% |
Octopus Investments Ltd.as of 04 Dec 2023 | 6.41m | 13.25% |
Canaccord Genuity Wealth Ltd.as of 30 Mar 2021 | 4.68m | 9.69% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 2024 | 1.76m | 3.63% |
City Asset Management Plcas of 29 Jan 2024 | 1.43m | 2.95% |
ICBC Standard Bank Plcas of 01 Feb 2024 | 610.00k | 1.26% |
Pilling & Co. Stockbrokers Ltd.as of 01 Feb 2024 | 267.00k | 0.55% |
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024 | 223.00k | 0.46% |
Acadian Asset Management LLCas of 01 Feb 2024 | 151.00k | 0.31% |
BG Fund Management Luxembourg SAas of 01 Feb 2024 | 137.00k | 0.28% |